CFN Media Releases Exclusive Video Series: Dr. Sue Sisley

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
125
CFN Media Releases Exclusive Video Series: Dr. Sue Sisley Unlocks Medical Marijuana Efficacy Through Science & Cultivation

SEATTLE, WA--(Marketwired - Apr 11, 2017) - CFN Media Group ("CFN Media", CannabisFN"), the leading agency and digital media network dedicated to the North American cannabis industry, today announced the release of a four-part video series focused on the work of renowned medical marijuana research scientist Dr. Sue Sisley, Director of Medical Plant Research for Heliospectra AB ( OTCQB : HLSPY ).

Dr. Sisley has pioneered research on the efficacy of medical cannabis as an effective treatment option for veterans suffering from chronic post-traumatic stress disorder (PTSD). In 2014, she secured a rare approval from the federal government to study the effects of marijuana on PTSD.

In 2015, Heliospectra AB, a world leader in intelligent lighting technology for greenhouse cultivation and plant research, hired Dr. Sisley as its Director of Medical Plant Research. Dr. Sisley and Heliospectra are working with cannabis growers to develop scalable medicinal cultivation methodologies while overseeing data collection and reporting with the company's medicinal cannabis growers in the U.S., Canada, and around the world.

Heliospectra has enabled Dr. Sisley to continue this groundbreaking research where she plans to publish all results -- good or bad -- to foster a better understanding of the plant and the transformative effect it can have on patients.

In this video series produced by CFN Media, Dr. Sisley outlines her research ambitions and the potential impact the studies could have on patients while highlighting why Heliospectra's lighting solutions represent a key breakthrough in the cultivation of medical cannabis.

Please follow the link to view the videos: http://www.cannabisfn.com/cfn-media-releases-...ltivation/

Heliospectra AB was founded in 2006 and is the industry's most proven intelligent lighting technology for greenhouse and controlled plant growth environments, with the vision to make commercial crop production more connected and resource-efficient. Growers and commercial producers across six continents use Heliospectra's holistic and flexible solutions to consistently increase yields while producing crops that achieve quality appearance, superior nutritional or medicinal value and longer shelf life, harvest after harvest. Winner of multiple international awards and recognitions, Heliospectra has raised more than $32 million in capital to date.

Learn how to become a CFN Media client company, brand or entrepreneur : http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id...?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Contact: Frank Lane 206 369 7050 flane@cannabisfn.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Zenas BioPharma Investors Urged to Join Class Action Lawsuit

Updated Category News Views 119

Overview of the Class Action Lawsuit Levi & Korsinsky, LLP is reaching out to investors in Zenas BioPharma, Inc. regarding a crucial class action lawsuit. This lawsuit may greatly impact those who have invested in Zenas BioPharma as it seeks to compensate individuals who have suffered losses due to alleged securities fraud. Understanding the Legal Landscape This class...

Continue Reading
Ayar Labs Raises $155 Million to Transform AI Infrastructure

Updated Category News Views 716

Ayar Labs Secures Significant Funding to Enhance AI Infrastructure Ayar Labs has recently secured $155 million in financing aimed at addressing the critical needs in AI infrastructure. With backing from prominent investors such as AMD Ventures, Intel Capital, and NVIDIA, alongside Advent Global Opportunities and Light Street Capital, this investment elevates the total...

Continue Reading
Transforming the Non-Profit Sector: The Impact Collaborative

Updated Category News Views 159

Impact Collaborative Launches to Transform the Non-Profit Sector Today marks a significant milestone with the launch of the Impact Collaborative (IC), a pioneering initiative aimed at revolutionizing the support provided to under-resourced communities. This innovative approach seeks to disrupt generational poverty while offering much-needed access to mental health and...

Continue Reading
Synovus Financial Corp Declares Quarterly Dividends for Investors

Updated Category News Views 128

Synovus Financial Corp Declares Quarterly Dividends Synovus Financial Corp. (NYSE: SNV) has recently revealed the details of its latest quarterly dividends. The board of directors has approved significant payouts to its shareholders, reinforcing the company’s ongoing commitment to deliver value to its investors. Details of the Declared Dividends The following dividends...

Continue Reading
Walnut Hill Medical Enhances Patient Access Through FDA TAP Program

Updated Category News Views 171

Walnut Hill Medical Partners with FDA in TAP Program Walnut Hill Medical, a prominent healthcare consultancy known for its market access and reimbursement strategies, has been chosen as an advisor to the FDA's Total Product Life Cycle Advisory Program (TAP). This initiative, which originated from the FDA's Center for Devices and Radiological Health (CDRH), aims to improve...

Continue Reading